Peptide Cycling Strategies: What Users Do and What's Known

Why Your Best Peptides Stop Working

It's a common story on peptide forums. Someone starts a run of ipamorelin and CJC-1295, and for the first 3-4 weeks they report sleeping well and recovering faster. Then, around week 6 or 8, the effects get... quieter. Some blame a 'bad batch.' Most guides blame the receptors.

The usual explanation is receptor desensitization, also known as tachyphylaxis. Think of your cell receptors like a doorbell. The first time someone rings it (the peptide), you answer immediately. If someone leans on it for an hour straight, you stop answering. Your body does something similar. Constant stimulation from exogenous peptides can cause the target receptors, primarily the growth hormone secretagogue receptor (GHSR), to downregulate. The cell pulls the receptors from its surface and internalizes them, or it uncouples them from the downstream signaling cascade. It's a protective mechanism to prevent overstimulation. In a 2004 cell culture study, the GHSR left the cell surface within 20-60 minutes of exposure to ghrelin, and surface binding took about 6 hours to recover.

If that's what is happening in people, then after a certain point, adding more peptide is like yelling at a disconnected phone. You're not getting the signal through. That's the logic behind cycling: giving your receptors a break so they can come back to the surface, ready to work again. But the human data are thin. The fade could also come from IGF-1 feedback, expectation, a training plateau, or gray-market product quality. As of October 2026, no controlled study has compared cycling schedules for any of these peptides.

The GH Secretagogue Dilemma: To Cycle or Not to Cycle

When people talk about cycling, most of the time they're talking about managing the receptors targeted by growth hormone releasing peptides (GHRPs) and growth hormone releasing hormone (GHRH) analogs. These all work to stimulate your pituitary to release more growth hormone (GH), but they ring different doorbells to do it.

• GHRPs (ipamorelin, GHRP-2, GHRP-6, hexarelin): These mimic a hormone called ghrelin and hit the GHSR directly. Hexarelin has the most human data on desensitization. In a 1998 study, 12 healthy older adults injected hexarelin twice daily for 16 weeks. Their GH response fell by about 30% after one week and about 45% by week 16, then returned to baseline 4 weeks after they stopped. So the loss was partial and reversible, not profound. Users describe a similar fade at around 4 weeks. Ipamorelin is often described as the cleanest, with the least effect on cortisol or prolactin, but no human study has measured its desensitization curve.
• GHRH analogs (CJC-1295, Mod GRF 1-29, tesamorelin): These hit the GHRH receptor. Guides describe this pathway as a bit more resilient than the GHSR, and the limited human data fit that: in 2006 trials of CJC-1295 in healthy adults, IGF-1 stayed above baseline for up to 28 days after repeated doses, and the authors saw a cumulative effect, not a fading one. Tesamorelin is an FDA-approved prescription medicine for abdominal fat in HIV-associated lipodystrophy.

This is why stacking a GHRH with a GHRP is so popular: you're hitting the pituitary from two different angles, and users commonly report a larger GH effect than either gives alone.

One result cuts against the idea that cycling is mandatory. In a 2-year randomized trial, 65 healthy adults aged 60-81 took MK-677 (ibutamoren), an oral compound that also acts on the GHSR, at 25 mg daily. GH and IGF-1 rose to young-adult levels and stayed there. MK-677 isn't a peptide and behaves differently from injected GHRPs, so this doesn't settle the question, but it does make "cycling is not optional" a community rule rather than an established finding. The usual community goal is to get the maximum benefit before downregulation kicks in hard, then take a break to let things reset.

Common GH Secretagogue Schedules

None of these schedules has been tested in a trial.

The Exception to the Rule: Healing Peptides

Here's where a lot of people go wrong: they apply the GH secretagogue cycling logic to everything.

For peptides like BPC-157 and TB-500 (a fragment of thymosin beta-4), the cycling logic is completely different. Users take them for a specific repair goal. In rodent and cell studies they work through different pathways: BPC-157 on angiogenesis via the VEGF pathway, and TB-500 on actin polymerization and cell migration. There is no evidence that their receptors (which are still being worked out) desensitize in the same way the GHSR does, though no study has looked. The evidence base is also much thinner: a 2025 systematic review of BPC-157 in sports medicine found 36 studies, 35 of them preclinical. As of October 2026, no controlled human trial of BPC-157 has published results, and FDA says it has found no human exposure data for the TB-500 fragment.

Users don't cycle healing peptides based on a calendar; they run them based on a goal, and stop when the tendonitis or muscle strain has resolved. A typical user-reported run is 4-8 weeks. The common forum reasoning: if you've run BPC-157 at 500 mcg/day for 6 weeks and your nagging elbow pain hasn't budged, running it for another 6 weeks is unlikely to help. The injury is either healing on its own, or the peptide isn't the right tool for that specific job. Reports are mixed. Some users describe clear improvement within weeks, while many report no benefit at 3-6 weeks.

Running BPC-157 for '12 weeks on, 4 weeks off' has no clear physiological rationale, since nobody has shown that tolerance develops.

Putting It All Together: A 16-Week Massing Cycle Example

Here's how users commonly combine the two approaches. It illustrates community practice, not a tested protocol. Say you're a powerlifter starting a 16-week hypertrophy block, and you're dealing with some patellar tendon pain.

• Weeks 1-12: The Growth Stack

  • Peptides (user-reported doses): CJC-1295 no DAC (about 100 mcg) + ipamorelin (about 200 mcg). Users report 100-300 mcg of each.
  • Timing: Most reports describe one dose before bed. Some users add a second ipamorelin dose post-workout.
  • Rationale: Users run this classic stack for GH pulses they say improve sleep quality and recovery between heavy sessions; no trial has measured those outcomes. The 12-week run follows the community rule of maximizing the window before significant receptor downregulation, not trial data.

• Weeks 1-6: The Repair Crew

  • Peptides (user-reported dose): BPC-157 (250 mcg twice daily), the top of the 250-500 mcg/day range users commonly report.
  • Timing: Many users inject subcutaneously near the site of the tendon pain. No human trial has compared injection sites.
  • Rationale: The goal here is targeted repair. Users treat 6 weeks as a trial period; whether that's long enough to change chronic tendinopathy in people is unknown. If the pain is gone, they discontinue the BPC-157, and if it hasn't changed, most stop anyway.

• Weeks 13-16: The Reset

  • Peptides: None.
  • Timing: N/A
  • Rationale: This is the community's standard 4-week 'off cycle' for the GH secretagogues, meant to let the GHSR and GHRH-R resensitize before the next cycle. The hexarelin study is the only human data behind that window.

Each component has a specific job and a specific timeline based on its proposed mechanism, not on a generic chart. For how these compounds compare with steroids over the longer term, see our 10-year comparison of peptides and AAS, and for results head to head, how specific peptides compare with AAS.

For tested athletes, cycling makes no difference: as of October 2026, WADA's Prohibited List bans all of these at all times. CJC-1295, tesamorelin, ipamorelin, hexarelin, MK-677 and the other GHRPs fall under S2.2.4, BPC-157 under S0, and TB-500 under S2.3. Legal status outside sport is covered in our guide to peptide legal frameworks.

What We Still Don't Know

• What causes the fade. Only one small trial (hexarelin, 12 older adults) has measured loss of GH response over months. Receptor desensitization, IGF-1 feedback, expectation and product quality haven't been separated.
• Whether a 4-week break is needed, enough, or more than needed. No trial has compared off periods.
• Whether GHRH analogs lose effect over months. The CJC-1295 trials ran 4-7 weeks.
• Whether BPC-157 helps human tendons at all. As of October 2026, a University of Arkansas Phase 1 trial of BPC-157 after rotator cuff repair (NCT07803250, about 30 participants) is registered but not yet recruiting, with a planned start in January 2027.